Please assess the completion status of the following clinical trial:

Trial Title: Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* men or women aged over 18 years~* recipient of kidney transplant (planned in next 24 hours)~Exclusion Criteria:~* recipients of multi-organ transplant~* previous treatment with Campath-1H~* active infection (including HIV, hepatitis B or C)~* history of anaphylaxis to humanized monoclonal antibody~* history of malignancy (except adequately treated non-melanoma skin cancer)~* loss of kidney transplant within 6 months not due to technical reasons~* medical history that might limit the individual's ability to take trial treatments for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab/Sirolimus (Type: EXPERIMENTAL): Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus
- Alemtuzumab/Tacrolimus (Type: EXPERIMENTAL): Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus
- Basiliximab/Tacrolimus (Type: ACTIVE_COMPARATOR): Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus
- Basiliximab/Sirolimus (Type: ACTIVE_COMPARATOR): Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).